SPY312.18+4.10 1.33%
DIA263.17+5.32 2.06%
IXIC9,682.91+74.54 0.78%

Cantor Fitzgerald Downgrades ANI Pharmaceuticals to Neutral, Lowers Price Target of $40

Cantor Fitzgerald analyst Brandon Folkes downgrades ANI Pharmaceuticals (NASDAQ:ANIP) from Overweight to Neutral and lowers the price target from $78 to $40.

Benzinga · 05/07/2020 18:18

Cantor Fitzgerald analyst Brandon Folkes downgrades ANI Pharmaceuticals (NASDAQ:ANIP) from Overweight to Neutral and lowers the price target from $78 to $40.